CCI-001 for Cancer
This trial is testing a new drug, called CCI-001, to see if it is safe for humans and to find the best dose. The drug is designed to attack cancer cells by binding to a protein that is important for cell division. The trial will also look at how well the drug works against different types of cancer.
- Recurrent and/or Metastatic Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
To what extent is this trial being participated in by individuals?
"Affirmative. According to the information posted on clinicaltrials.gov, enrollment is currently open for this medical trial which was initially shared on July 26th 2021 and last updated on July 12th 2022. A total of 70 patients must be recruited from a single centre."
What objectives are the researchers hoping to accomplish with this experiment?
"The core aim of this biomedical trial is to identify the optimal dosage for intravenously delivered CCI-001 during Cycle 1 (28 days). Additional objectives include assessing patient survival rates, determining response rate based on RECIST 1.1 criteria and calculating the terminal half life of CCI-001 in patients' plasma."
Has CCI-001 been sanctioned by the FDA?
"Since this is a Phase 1 trial, the safety of CCI-001 was estimated to be a score of 1 due to limited data backing its efficacy and security."
Are there any open enrollment opportunities for this trial?
"The clinical trial, which was uploaded to clincialtrials.gov on July 26th 2021 and last revised on the 12th of July 2022, is still in need of participants at this time."